pyrazines has been researched along with decitabine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Giles, FJ | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S | 1 |
| Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F | 1 |
| Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H | 1 |
| Estey, EH; Percival, MM | 1 |
| Naoe, T | 1 |
| Furukawa, Y; Ito, R; Iwama, A; Iwano, S; Kayamori, K; Koide, S; Lennox, W; Mimura, N; Miyawaki, A; Nagai, Y; Nakajima-Takagi, Y; Oshima, M; Sakaida, E; Sheedy, J; Shinoda, D; Tohyama, K; Weetall, M; Yamaguchi, K; Yamazaki, S; Zhong, C | 1 |
3 review(s) available for pyrazines and decitabine
| Article | Year |
|---|---|
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
1 trial(s) available for pyrazines and decitabine
| Article | Year |
|---|---|
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic | 2012 |
3 other study(ies) available for pyrazines and decitabine
| Article | Year |
|---|---|
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A | 2013 |
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29 | 2014 |
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Decitabine; G2 Phase; Heterografts; HL-60 Cells; Humans; Mice; Myelodysplastic Syndromes; Paclitaxel; Pyrazines; Sequence Analysis, RNA; Tubulin; Tubulin Modulators; Vincristine | 2020 |